Index

Note: Page numbers of article titles are in boldface type.

A

Ablation, VT, 201–211. See also Ventricular tachycardia (VT) ablation.
Activation mapping, VT ablation and, 206
Active compression decompression (ACD) device, 23–24
Acute heart failure, heart transplantation for, WCD between, 136–137
AEDs. See Automated external defibrillators (AEDs).
Age, as factor in SCD, 5–6
American College of Cardiology/American Heart Association/Heart Rhythm Society (ACC/AHA/HRS) practice guidelines, on ICDs in coronary artery disease patients, 83–84
Anemia, SCD in ESRD patients due to, 63
Antiarrhythmic agents
for cardiac arrest, 25–27
in SCD prevention in ESRD patients, 67
Arrhythmia(s)
cardiac, during cardiac arrest, 33
ventricular, in CKD/ESRD patients, 61–62
Arrhythmogenic disorders, inherited, WCD for patients with, 137
Automated external defibrillators (AEDs), 33–40
advanced directives for, 38
civil liability and, 38
cost-effectiveness of, 38
ICDs and, WCD between, 142–145
in home, 44
in schools, 44
lay responders use, 34–36
Automatic defibrillation, 120

B

Biomarker(s), as predictor of SCD in ESRD patients, 69–70
Biotronik HM, 194
ß-Blockers, in SCD prevention in ESRD patients, 65–66
Boston Scientific LATITUDE Patient Management System, 194

C

CABG-Patch study, 98
Calcium/phosphorus/parathyroid hormone, SCD in ESRD patients due to, 63
Cardiac arrest
cardiac arrhythmias during, 33
management of
community approach in, 46–47
pharmacologic, 24–27
antiarrhythmic agents, 25–27
vasoactive medications, 24–25
reperfusion therapy in, 27–28
phases of, 13
prevention of, ICDs in, 129–130
sudden
“chain of survival” for, 41
death due to, 41
survival from, 13
Cardiac arrest champion, 47
Cardiac arrest registry, as community resource, 47
Cardiac Arrest Registry to Enhance Survival (CARES) project, 47
Cardiac arrhythmia(s), during cardiac arrest, 33
Cardiac Arrhythmia Suppression Trial (CAST), 123–124
Cardiac care, postarrest, optimizing of, 45–46
Cardiac death, sudden. See Sudden cardiac death (SCD).
Cardiac Pacemakers, Inc., 120–125
challenges facing, 122–123
described, 120–121
suppliers of, 124
technology development at, 121–122
transvenous defibrillation by, 123
Cardiac resuscitation
ILCOR/ACC/AHA guidelines for, 33
keeping pace with science of, 38–39
Cardiac Resynchronization-Heart Failure trial, 99
Cardiomyopathy(ies), nonischemic, ICD therapy in patients with, nonsignificance of, 107
Cardiomyopathy Trials, 98
Cardiopulmonary resuscitation (CPR)
advances in, 13–31
chest-wall decompression, 19–24. See also Chest-wall decompression, CPR in.
compressions, 17–19
therapeutic hypothermia, 24
ventilations, 15–17
bystander, 41–43
training for, 42
chest-wall decompression by, 19–24. See also Chest-wall decompression, CPR in.
compression in, 17
compression-only, 17–19
dispatcher-assisted telephone, 45
hands-only, 17–19

doi:10.1016/S1877-9182(09)00026-4
1877-9182/09/$ – see front matter © 2009 Elsevier Inc. All rights reserved.
Cardiopulmonary (continued)
immediate, 14
improving circulation by, 14–15
mass training, 43
professional, 45
simplified technique, 43
systems-based approach to, 27–28
ventilations during, 15–17
Cardioverter-defibrillators, implantable. See
Implantable cardioverter-defibrillator (ICD).
CARES (Cardiac Arrest Registry to Enhance Survival) project, 47
CAST. See Cardiac Arrhythmia Suppression Trial (CAST).
“Chain of survival,” in sudden cardiac arrest, 41
Chest-wall decompression, CPR in, 19–24
devices for, 20–24
ACD, 23–24
harnessing negative intrathoracic pressure to increase venous return and increase vital organ perfusion, 20–23
CHF. See Congestive heart failure (CHF).
Children, subcutaneous ICD in, 148
Chronic kidney disease (CKD)
defined, 61
hemodialysis for, prevalence of, 61
prevalence of, 61
SCD and, ventricular arrhythmias and, 61–62
Circulation, improving, CPR in, 14–15
Civil liability, AEDs and, 38
CKD. See Chronic kidney disease (CKD).
Community resources, in SCD prevention, 41–50.
See also Sudden cardiac death (SCD), prevention of, community resources in.
COMPANION trial, 99
Comparison of Medical Therapy Pacing Defibrillation in Heart Failure (COMPANION) trial, 99
Compression(s), during CPR, 17
Compression-only CPR, 17–19
Congestive heart failure (CHF), SCD in ESRD patients due to, 64
Coronary Artery Bypass Graft-Patch (CABG-Patch) study, 98
Coronary artery disease
ICD in patients with, 79–93. See also Implantable cardioverter-defibrillator (ICD), in coronary artery disease patients.
SCD in patients with, 4
cause of, 95
prevalence of, 79
Coronary revascularization, in SCD prevention in ESRD patients, 69
de, early, in SCD prevention, 43–44
public access, 33–40. See also Public access defibrillation.
transvenous, Cardiac Pacemakers, Inc. in, 123
Defibrillator(s)
automated external, 33–40. See also Automated external defibrillators (AEDs).
external, in SCD prevention in ESRD patients, 68–69
implantable. See specific types.
Defibrillators in Acute Myocardial Infarction Trial (DINAMIT), 98–99
Defibrillators in Non-Ischemic Cardiomyopathy Treatment Evaluations (DEFINITE) trial, 98
DEFINITE trial, 98
Diabetes mellitus, SCD and, 5
Dialysis
delivery methods, changes in, in SCD prevention in ESRD patients, 65
SCD in ESRD patients due to, 63
DINAMIT, 98–99
Dispatcher-assisted telephone CPR, 45
Drug(s), in recurrence prevention of inappropriate ICD therapy, 163
Dual-chamber ICDs, inappropriate therapy with, recurrence prevention of, 167
E
Early defibrillation, in SCD prevention, 43–44
Electrocardiography (ECG), signal average, SCD and, 53–54
Emergency medical services (EMS), in SCD prevention, 44–45
community role in, coordinating of, 44–45
EMS. See Emergency medical services (EMS).
Endotak II trial, 124–125
Endotak trial, 123
End-stage renal disease (ESRD) mortality related to, 61
SCD and, 61–77
CHF and, 64
hypertension and, 64
LVH and, 64
mechanisms of, 62–65
anemia, 63
calcium/phosphorus/parathyroid hormone, 63
dialysis, 63
myocardial ischemia/infarction, 63–64
potassium, 62–63
renal milieu, 62–63
uremia, 63
predictors of, 69–70
biomarkers, 69–70
electrocardiographic, 69
MTWA, 69
prevalence of, 61
prevention of, therapies in, 65–69
antiarrhythmic drugs, 67
ß-blockers, 65–66
coronary revascularization, 69
device therapy, 67–69
external defibrillators, 68–69
3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, 66–67
implantable defibrillators, 67–68
medical, 65
RAAS inhibition, 66
risk factors for, 63–65
sympathetic nervous system activation and, 64–65
ventricular arrhythmias and, 61–62
ESRD. See End-stage renal disease (ESRD).
External defibrillators
automated. See Automated external defibrillators (AEDs).
in SCD prevention in ESRD patients, 68–69

F
Fascicular VTs, in patients with normal hearts, ablation for, 207

G
Gender, as factor in SCD, 5–6
Genetic factors, in SCD, 6–7

H
Heart disease, structural, VT ablation in, 203–206
Heart failure
acute, heart transplantation for, WCD between, 136–137
congestive, SCD in ESRD patients due to, 64
pacing for, Endotak II trial and, 124–125
Heart surgery, poor ventricular function after, WCD for, 135
Heart transplantation, acute heart failure and, WCD between, 136–137
Heart-rate turbulence, SCD and, 54
Heart-rate variability, SCD due to, 52–53
Hemodialysis, for CKD, prevalence of, 61
Home, AEDs in, 44
Housecall Plus Remote Patient Monitoring System, 195
3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, in SCD prevention in ESRD patients, 66–67
Hypertension, SCD in ESRD patients due to, 64
Hypothermia, therapeutic, 24
in postarrest cardiac care, 45–46

I
ICD. See Implantable cardioverter-defibrillator (ICD).
ILCOR/ACC/AHA guidelines. See International Liaison Committee on Resuscitation–American College of Cardiology–American Heart Association (ILCOR/ACC/AHA) guidelines.
Implantable cardioverter-defibrillator (ICD), 46
automatic defibrillation, 120
clinical trials of, 51
development of, 117–127
Cardiac Pacemakers, Inc. in, 120–125. See also Cardiac Pacemakers, Inc.
early days, 117–118
dual-chamber, inappropriate therapy with, recurrence prevention of, 167
follow-up after, future of, 193–200. See also Implantable cardioverter-defibrillator (ICD), remote monitoring with.
historical background of, 129
in coronary artery disease patients, 79–93
clinical trials of, 80–84
ACC/AHA/HRS practice guidelines, 83–84
clinical approach to risk stratification in patients with LV dysfunction, 88–89
in patients with low risk for arrhythmic mortality, 88
primary prevention, 80–83
in risk subsets, 85–89
risk of arrhythmic and nonarrhythmic mortality, 87–88
secondary prevention, 80
time dependence after coronary revascularization and acute coronary events, 85–87
cost-effectiveness of, 90
inappropriate therapies, 89
quality of life with, 89–90
in patients with nonischemic cardiomyopathy, nonsignificance of, 107
in SCD primary prevention
cost-effectiveness of, 111–113
development of, 96
guidelines adherence, 95–103
hardware malfunction in, 111
implantation of, guidelines for, 99–101
in postmyocardial infarction setting, 106–107
pacing hazards in, 110–111
randomized controlled trials of, 96–99
cardiac resynchronization trials, 99
MADIT, 96–97
MADIT II, 51, 97
methodologic issues in, 107–108
MUSTT, 97
real-world patients vs. patients in, 108–109
SCD-HeFT, 98
Implantable (continued)
trials demonstrating no difference in all-cause mortality, 98–99
restraint related to, 105–116
described, 105–106
shocks from natural history of patients and, 111–113
types of, 109–110
inappropriate therapy with, 155–171
causes of, 158
described, 155–158
incidence of, 158–160
pathophysiology of, 160–161
recurrence of, prevention of, 163–167
AV relationship in, 167
device reprogramming in, 163
interval-based discriminators in, 163–166
morphology-based discriminators in, 166–167
pharmacologic approaches to, 163
risk factors for, 158
industrialization of, 125–127
infections due to, WCD in place of, 137–141
lead of, 173–191. See also Implantable cardioverter-defibrillator (ICD) lead.
mortality associated with, 155
oversensing of ventricular activity with, 161–163
pacing midlife crises in, 118–120
protection with, WCD for, 137–141
rapid ventricular rate with, detection of, 161–163
remote monitoring with, 193–200
clinical impact of, 195–198
cost-effectiveness of, 197
historical background of, 193–194
in clinical events detection, 196
in device-related events detection, 196–197
medical legal issues related to, 198
morbidity and mortality related to, 197
outcomes of, 197
reimbursement for, 197–198
systems for, 194–195
utilization of, 197
subcutaneous
advantages of, 151–152
disadvantages of, 152
experimental evidence for, 147–149
in adults, experimental models of, 148–149
in children, 148
initial studies, 147–148
limitations of, 149–151
technology related to, 147–154
totally, in adults, 149
WCD as bridge to, 129–146. See also Wearable cardioverter defibrillator (WCD).
Implantable cardioverter-defibrillator (ICD) lead, 173–191
basic concepts of, 173–174
conductors in, 174–180
connector pins in, 179, 180
construction of, 179–184
defibrillation coils in, 179, 180
described, 173, 180–184
design of, 179–184
failure of, 184–186
detection of, 188–189
management of patients with, 186–188
monitoring of, 188–189
reporting of, 188–189
insulation in, 174–179
materials of, 174–179
pacing electrodes in, 179
yoke design in, 180
Implantable defibrillators. See also specific types.
in SCD prevention in ESRD patients, 67–68
Infarction(s), myocardial. See Myocardial infarction (MI).
Infection(s), ICD-related, WCD in place of, 137–141
Inherited arrhythmogenic disorders, WCD for patients with, 137
International Liaison Committee on Resuscitation–American College of Cardiology–American Heart Association (ILCOR/ACC/AHA) guidelines, for cardiac resuscitation, 33, 38
Interval-based discriminators, in prevention of recurrence of inappropriate ICD therapy, 163–166
Ischemia(s), myocardial, SCD in ESRD patients due to, 63–64

K
Kidney disease, chronic. See Chronic kidney disease (CKD).

L
Lead(s), ICD. See Implantable cardioverter-defibrillator (ICD) lead.
Left ventricular (LV) dysfunction, SCD and, 4–5
Left ventricular hypertrophy (LVH), SCD in ESRD patients due to, 64
Legal issues, remote monitoring with ICDs and, 198
Liability(ies), civil, AEDs and, 38
LVH. See Left ventricular hypertrophy (LVH).

M
MADIT, 96–97
MADIT II, 51, 97
Mapping
activation, VT ablation and, 206
pace, VT ablation and, 206–207
Medtronic CareLink Network, 194–195
Microvolt T-wave alternans (MTWA)
as predictor of SCD in ESRD patients, 69
SCD and, 55–56
Morphology-based discriminators, in recurrence prevention of inappropriate ICD therapy, 166–167 MTWA. See Microvolt T-wave alternans (MTWA).

Multicenter Automatic Defibrillator Implantation Trial (MADIT), 96–97

Multicenter Automatic Defibrillator Implantation Trial II (MADIT II), 51, 97

Multicenter Unsustained Tachycardia Trial (MUSTT), 97

MUSTT, 97

Myocardial infarction (MI)

SCD due to, 1 incidence of, 1 SCD in ESRD patients due to, 63–64 WCD after, 133–135

Myocardial ischemia, SCD in ESRD patients due to, 63–64

N

1979 World Symposium on Cardiac Pacing, 120

Nonischemic cardiomyopathy, ICD therapy in patients with, nonsignificance of, 107

O

OTVTs. See Outflow tract VTs (OTVTs).

Outflow tract VTs (OTVTs), ablation for, 207

P

Pace mapping, VT ablation and, 206–207

Postarrest cardiac care, optimizing of, 45–46

Potassium, SCD in ESRD patients due to, 62–63

Professional CPR, 45

Public access defibrillation, 33–40 advanced directives for, 38 AEDs in, 33–40 cost-effectiveness of, 38 in SCD prevention, 43–44 programs for, 36–37 public awareness and education related to, 37–38 Public access defibrillators, programs for, community involvement in, 44

Q

Quality of life, ICDs in coronary artery disease patients and, 89–90

R

RAAS inhibition. See Renin-angiotensin-aldosterone system (RAAS) inhibition.

Remote monitoring, with ICD, 193–200. See also Implantable cardioverter-defibrillator (ICD), remote monitoring with.

Renin-angiotensin-aldosterone system (RAAS) inhibition, in SCD prevention in ESRD patients, 66

Reperfusion therapy, 27

Resuscitation cardiac ILCOR/ACC/AHA guidelines for, 33 keeping pace with science of, 38–39 cardiopulmonary. See Cardiopulmonary resuscitation (CPR).

Resuscitation centers, regionalization of, 45–46

S

SCD. See Sudden cardiac death (SCD).

SCD-HeFT. See Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT).

School(s)

AEDs in, 44 CPR in, 42–43 Signal average ECG, SCD and, 53–54 Single-chamber ICDs, inappropriate therapy with, recurrence prevention of, 163–166 Socioeconomic status, as factor in SCD, 7 St. Jude Medical Merlin.net Patient Care Network, 195 Structural heart disease, VT ablation in, 203–206 Subcutaneous ICD, 147–154. See also Implantable cardioverter-defibrillator (ICD), subcutaneous.

Sudden cardiac arrest

“chain of survival” for, 41 death due to, 41

Sudden cardiac death (SCD)

arrhythmic mechanisms of, 1–2 coronary artery disease and cause of, 95 prevalence of, 79 death due to, 41 prevalence of, 13, 51, 79, 95 defined, 1 described, 1 epidemiology of, changing of, 1–11 ESRD and, 61–77. See also End-stage renal disease (ESRD), SCD and.

global outlook for, 7–9 heart-rate turbulence and, 54 heart-rate variability and, 52–53 in CKD/ESRD patients, 61–62 MTWA and, 55–56 prevention of community resources in, 41–50 bystander CPR, 41–43 community approach, 46–47 coordination and administration of, 46–48 early defibrillation, 43–44 EMS systems, 44–45 postarrest care, optimizing of, 45–46 public access defibrillator programs, 44 schools, 42–43 AEDs in, 44
Index

Sudden (continued)
primary, ICDs in, 95–103. See also Implantable cardioverter-defibrillator (ICD), in SCD primary prevention.

risk factors for, 2–7
age, 5–6
coronary artery disease, 4
diabetes mellitus, 5
gender, 5–6
genetic factors, 6–7
LV dysfunction, 4–5
socioeconomic status, 7

risk stratification for, 51–59
clinical significance in, 56–57
current perspective on, 57
future directions in, 57
tests for, comparison among, 57
signal average ECG and, 53–54

Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT), 51, 98

Sympathetic nervous system, activation of, SCD in ESRD patients due to, 64–65

Syncope of unknown origin, WCD for, 137

T
Tachycardia, ventricular. See Ventricular tachycardia (VT).

Telephone CPR, dispatcher-assisted, 45

Transplantation, heart, acute heart failure and, WCD between, 136–137
Transvenous defibrillation, Cardiac Pacemakers, Inc. in, 123

U
Uremia, SCD in ESRD patients due to, 63

V
Vasoactive medications, for cardiac arrest, 24–25

Ventilation, during CPR, 15–17

Ventricular arrhythmias, in CKD/ESRD patients, 61–62

Ventricular tachycardia (VT)
fascicular, in patients with normal hears, ablation for, 207
outflow tract, ablation for, 207

Ventricular tachycardia (VT) ablation, 201–211
activation mapping and, 206
for fascicular VTs, 207
for OTVVs, 207
for specific VTs, 207–209
in structural heart disease patients, 203–206
indications for, 202
pace mapping and, 206–207
preprocedural planning for, 202–203
technical considerations for, 203
timing of, 202

VT. See Ventricular tachycardia (VT).
VT ablation. See Ventricular tachycardia (VT) ablation.

W
WCD. See Wearable cardioverter defibrillator (WCD).

Wearable cardioverter defibrillator (WCD), 129–146
after heart surgery with poor ventricular function, 135
after myocardial infarction, early phase, 133–135
between acute heart failure and heart transplantation, 136–137
between ICDs and AEDs, 142–145
clinical aspects of, 141–142
for patients with inherited arrhythmogenic disorders, 137
for syncope of unknown origin, 137
ICD infections and, 137–141
indications for, 133–141
technical characteristics of, 130–133